Overall, as the study concludes, the anatabine supplement was safe and well tolerated, although it was associated with more minor adverse events on initial dose adjustment. The most common MedDRA adverse events upon starting anatabine supplementation were mild dizziness (36%), nausea (8%), headaches (7%), and paresthesia (7%); most of the events were resolved with simple dose adjustment. Very few patients withdrew from the study due to adverse events (7 on anatabine and 1 on placebo). There were no significant abnormalities in clinical laboratory values attributed to anatabine, and no clinically significant effects of supplementation, either with anatabine or placebo, on vital sign measures.
Curtis Wright, MD, MPH, Medical Director of Rock Creek Pharmaceuticals, commented, "The concept for this clinical trial originated after receiving reports from individuals that the addition of anatabine, a Solanaceous alkaloid, to their diet improved their thyroid inflammatory disease. The idea was supported by multiple recent epidemiological st
|SOURCE Star Scientific, Inc.|
Copyright©2012 PR Newswire.
All rights reserved